QLINEA Stock Overview
Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Q-linea AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr2.84 |
| 52 Week High | kr110.00 |
| 52 Week Low | kr2.61 |
| Beta | 0.43 |
| 1 Month Change | -13.15% |
| 3 Month Change | -70.14% |
| 1 Year Change | -96.17% |
| 3 Year Change | -95.85% |
| 5 Year Change | n/a |
| Change since IPO | -95.79% |
Recent News & Updates
Shareholder Returns
| QLINEA | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -4.7% | -1.8% | 0.2% |
| 1Y | -96.2% | -20.0% | 2.2% |
Return vs Industry: QLINEA underperformed the Swedish Medical Equipment industry which returned -21.2% over the past year.
Return vs Market: QLINEA underperformed the Swedish Market which returned -0.6% over the past year.
Price Volatility
| QLINEA volatility | |
|---|---|
| QLINEA Average Weekly Movement | 10.5% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in SE Market | 12.3% |
| 10% least volatile stocks in SE Market | 4.2% |
Stable Share Price: QLINEA is more volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: QLINEA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 149 | Jonas Jarvius | https://qlinea.com |
Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in the United Kingdom. It offers ASTar, an antibiotic susceptibility testing system used for positive blood cultures; and in vitro diagnostics systems for infectious diseases. The company serves healthcare providers.
Q-linea AB (publ) Fundamentals Summary
| QLINEA fundamental statistics | |
|---|---|
| Market Cap | kr82.95m |
| Earnings (TTM) | -kr257.34m |
| Revenue (TTM) | kr7.59m |
10.9x
P/S Ratio-0.3x
P/E RatioIs QLINEA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QLINEA income statement (TTM) | |
|---|---|
| Revenue | kr7.59m |
| Cost of Revenue | kr18.82m |
| Gross Profit | -kr11.23m |
| Other Expenses | kr246.11m |
| Earnings | -kr257.34m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Jul 13, 2023
| Earnings per share (EPS) | -8.81 |
| Gross Margin | -147.95% |
| Net Profit Margin | -3,389.69% |
| Debt/Equity Ratio | 24.1% |
How did QLINEA perform over the long term?
See historical performance and comparison